OptimizeRx Co. (NASDAQ:OPRX)’s share price shot up 14.6% on Monday . The company traded as high as $10.93 and last traded at $10.36, 203,793 shares changed hands during mid-day trading. An increase of 121% from the average session volume of 92,389 shares. The stock had previously closed at $9.04.
A number of brokerages have issued reports on OPRX. TheStreet downgraded OptimizeRx from a “c” rating to a “d+” rating in a report on Wednesday, November 20th. ValuEngine upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Finally, Zacks Investment Research lowered OptimizeRx from a “hold” rating to a “sell” rating in a research report on Tuesday, November 5th.
The company has a debt-to-equity ratio of 0.01, a current ratio of 7.00 and a quick ratio of 7.00. The company’s 50 day simple moving average is $11.28 and its 200 day simple moving average is $14.11. The company has a market capitalization of $128.13 million, a PE ratio of 207.20 and a beta of 0.37.
OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.15). OptimizeRx had a negative return on equity of 3.68% and a negative net margin of 5.32%. The company had revenue of $5.00 million for the quarter, compared to analysts’ expectations of $7.21 million. On average, equities analysts forecast that OptimizeRx Co. will post -0.04 EPS for the current year.
In related news, CEO William J. Febbo purchased 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were purchased at an average cost of $10.38 per share, for a total transaction of $51,900.00. Company insiders own 8.40% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN boosted its stake in OptimizeRx by 9.5% in the second quarter. Wells Fargo & Company MN now owns 13,562 shares of the company’s stock valued at $219,000 after acquiring an additional 1,180 shares in the last quarter. Barclays PLC increased its position in shares of OptimizeRx by 34.7% during the third quarter. Barclays PLC now owns 10,403 shares of the company’s stock worth $151,000 after purchasing an additional 2,678 shares in the last quarter. California State Teachers Retirement System increased its position in shares of OptimizeRx by 16.5% during the third quarter. California State Teachers Retirement System now owns 21,500 shares of the company’s stock worth $311,000 after purchasing an additional 3,049 shares in the last quarter. Strs Ohio purchased a new stake in shares of OptimizeRx in the 2nd quarter valued at about $51,000. Finally, Squarepoint Ops LLC lifted its holdings in shares of OptimizeRx by 25.0% in the 3rd quarter. Squarepoint Ops LLC now owns 27,000 shares of the company’s stock valued at $391,000 after purchasing an additional 5,400 shares during the last quarter. 60.64% of the stock is owned by hedge funds and other institutional investors.
OptimizeRx Company Profile (NASDAQ:OPRX)
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Further Reading: Bollinger Bands
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.